Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
Recruiting
N/A
Interventional Study
Myoma;Uterus
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 25 – 48
- Sex
- Female
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 40 (estimated)
- Sponsor
- Cairo University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.
The main questions it aims to answer are:
Does intramyometrial ergometrine reduce intraoperative and postoperati…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female participants aged 25 to 48 years
* Body mass index (BMI) \< 35 kg/m²
* Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms)
* Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagn…
Contacts